Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint-Reference-Cited by-同舟云学术

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

Published:2014-01 Issue:1 Volume:15 Page:e42-e50
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hellmann Matthew D,Chaft Jamie E,William William N,Rusch Valerie,Pisters Katherine M W,Kalhor Neda,Pataer Apar,Travis William D,Swisher Stephen G,Kris Mark G

Publisher

Elsevier BV

Subject

Oncology

Reference75 articles.

1. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer;Arriagada;N Engl J Med,2004

2. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer;Winton;N Eng J Med,2005

3. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial;Douillard;Lancet Oncol,2006

4. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups;Strauss;J Clin Oncol,2008

5. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review;Gilligan;Lancet,2007

Cited by 471 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A2ST-GCM: An adaptive spatio-temporal aware graph convolutional model for predicting pathological complete response in neoadjuvant therapy;Biomedical Signal Processing and Control;2025-01

2. Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy;The Breast;2024-12

3. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario;Current Oncology;2024-08-30

4. The comparison of perioperative outcomes and disease-free survival between pneumonectomy after immunochemotherapy and after isolated chemotherapy: one single center experience;Journal of Cardiothoracic Surgery;2024-08-28

5. Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection;Cancers;2024-08-20